Core Viewpoint - OneMedNet Corporation is advancing its commercial launch of the RWD Platform powered by Palantir Foundry, converting customer evaluations into subscriptions and reinforcing its position in the life sciences and healthcare sectors [1][4]. Group 1: Commercial Launch and Subscription Growth - The launch is driving rapid expansion of subscription contracts, including multi-year deals that represent millions in incremental recurring revenue [2]. - The OneMedNet iRWD™ network has over 2,130 healthcare sites, and as it scales, the subscription value increases due to greater scale, diversity, real-time access, and analytical depth [2][4]. Group 2: Customer Feedback and Platform Strengths - Customer feedback confirms the platform's strengths, including unmatched analytical depth, accelerated cohort feasibility, streamlined workflows, and faster onboarding of data partners [3]. - The platform provides near real-time access to comprehensive regulatory-grade multimodal RWD, enhancing study design and evidence generation [5][6]. Group 3: Investor Benefits - The commercial launch supports OneMedNet's high-margin recurring revenue model, with evaluation conversions to multi-year subscriptions expected to drive predictable growth and millions in incremental annual recurring revenue [4]. - Network expansion is anticipated to boost deal sizes and penetration in life sciences, AI, and research sectors, fueling sustained bookings [4]. Group 4: Company Overview and Industry Impact - OneMedNet is revolutionizing access to Real-World Data (RWD) through its iRWD™ platform, which harnesses data from over 2,130 healthcare sites, impacting drugmakers, medical device innovators, and AI developers [8]. - The company's proprietary AI also anonymizes data for other industries, such as finance and retail, enhancing project de-risking and secure data sharing [9].

Core Insights - HEALWELL AI's DARWEN™ AI Platform is one of the first to generate regulatory-grade real-world data (RWD) to enhance patient access and advance the pharmaceutical industry [3][4][6] - The collaboration with Takeda Pharmaceutical showcased the platform's ability to improve remission outcomes in ulcerative colitis and Crohn's disease through vedolizumab dose escalation [4][6] - HEALWELL's unique AI-driven RWD generation capability is expected to significantly impact clinical and commercial value in healthcare [3][6] Company Overview - HEALWELL AI Inc. focuses on preventative care using artificial intelligence to improve healthcare outcomes through early disease detection [9] - The company is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under "HWAIF" [9] - HEALWELL has been recognized for its leadership in healthcare AI, being named a finalist in Newsweek's AI Impact Awards 2025 [7][8] Industry Impact - The use of AI in generating RWD is a transformative approach that can lead to more precise and effective patient-centered care [5][6] - The platform's ability to extract clinically meaningful insights from electronic health records positions HEALWELL at the forefront of healthcare AI innovation [5][6] - The advancements in RWD generation are expected to facilitate faster and more accurate development of pharmaceutical products, ultimately improving patient outcomes [5][6]

As filed with the Securities and Exchange Commission on December 15, 2023 Registration No. 333-[__] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ONEMEDNET CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 3721 86-2049355 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) OneMedNet Cor ...